Medtronic, along with its technology partner IBM Watson Health, has announced commercially availability of artificial intelligence (AI) powered Sugar.IQ diabetes management app.
Sugar.IQ smart diabetes assistant is a first-of-its-kind intelligent app, which will help simplify and improve daily diabetes management.
According to Medtronic, around 30.3 million Americans have been diagnosed with diabetes, with 1.5 million new cases being diagnosed each year.
The new smart diabetes assistant is said to leverage AI and analytic technologies from IBM Watson Health to continually analyze how an individual’s glucose level responds to their food intake, insulin dosages, daily routines and other factors such as information offered by the app user.
Through taking the support of Sugar.IQ app, people with diabetes can bring out patterns that affect their glucose levels, enabling to make small adjustments across the day.
Sugar.IQ assistant discovers patterns that are hard to see, helping to provide meaningful and personalized insights to the people with diabetes.
The insights demonstrate how lifestyle choices, medications, and multiple daily injections impact diabetes management and the time spent with glucose in the target range.
Through using AI and advanced analytics, the app offers users with a complete view of their current levels, as well as insights and individualized guidance to understand and manage daily diabetes management decisions.
Medtronic said the Sugar.IQ app is available to users of its Guardian connect system, which is claimed to be the first smart standalone CGM system designed to help people with diabetes using multiple daily injections (MDI) with actionable tools.
The Sugar.IQ assistant and Guardian Connect CGM offers people with more tools to stay in range with customizable predictive alerts up to 60 minutes before a high or low.
Medtronic employee and registered nurse (RN) Michelle Shaw said: “Sugar.IQ has given me insights that I could never have uncovered on my own – even with 30 years of diabetes experience. It’s been eye opening and fun to gain new insights into my diabetes without additional burden.”